Monges Viviane sold 11,969 shares of Pharvaris N.V. at $33.05 for −$396k on Sep 23, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Director
DIR
Filed Sep 25, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$395,523.98Shares × reported price
Shares traded
11,969Common Stock
Price per share
$33.05Reported price. Read footnotes for ranges.
% of reported position traded
68.52%This security and ownership context
Holdings after
5,500Direct
Trade date
Sep 23, 2026Sell
Filed
Sep 25, 2026, 1:35 PM ET2-day reporting delay
Accession
0001193125-26-402567Code S · Transaction 229664
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 17,469 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 23, 2026Option exercise11,969$8.05$96,350.45Trade 229663
Sep 23, 2026Option exercise11,969$0.00$0Trade 229665
3 transaction rows in this filing. Joint filers share the same rows.

PHVS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
PHVS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +17%1w ago +17%1d ago +9.9%
Returns since7d −2.6%30d −1.9%90d180d1y

Footnotes in full

F1: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $33.00 to $33.0801. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F2: 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.